Importantly, the risk of CRC in T2DM is significantly modulated by antidiabetic treatment; insulin increases, while metformin, the first-choice oral antidiabetic, reduces cancer risk by interfering with hyperactive Notch1 and mTOR signaling [20,21]. The gene discussed is INS; the disease is cancer.